Redefining GVHD Prophylaxis: The Expanding Horizon of Posttransplant Cyclophosphamide
Advances in Experimental Medicine and Biology, Springer, ss.87-96, 2026
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/5584_2025_873
- Yayınevi: Springer
- Sayfa Sayıları: ss.87-96
- Anahtar Kelimeler: GVHD, Haploidentical, Immune tolerance, Matched, Posttransplant cyclophosphamide (PTCy), Prophylaxis, Stem cell transplantation
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Posttransplant cyclophosphamide (PTCy) represents a paradigm shift in the prevention of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT). As a high-dose, posttransplant immunomodulatory agent, PTCy offers a unique mechanism to facilitate graft tolerance, mitigate GVHD, and preserve graft-versus-leukemia (GVL) effects. The beneficial effects of PTCy on GVHD appears to be independent of donor type, graft source, or conditioning regimen intensity. This chapter provides an in-depth analysis of the mechanisms underlying PTCy and its clinical applications in haploidentical, HLA-matched, and -mismatched HSCT, highlighting its transformative impact in transplantation medicine. PTCy is emerging as a new standard GVHD prophylaxis for all HSCT settings.